1-Oleyl-lysophosphatidic acid (LPA) promotes polarization of BV-2 and primary murine microglia towards an M1-like phenotype

Journal of Neuroinflammation

Volumn 13, Issue 1, 2016, Pages

  Plastira, Ioanna ^a   Bernhart, Eva ^a   Goeritzer, Madeleine ^a,b   Reicher, Helga ^a   Kumble, Vishwanath Bhat ^a   Kogelnik, Nora ^a   Wintersperger, Andrea ^a   Hammer, Astrid ^a   Schlager, Stefanie ^a   Jandl, Katharina ^a   Heinemann, Akos ^a   Kratky, Dagmar ^a,b   Malle, Ernst ^a   Sattler, Wolfgang ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BIOTECHMED GRAZ   (Austria)

Author keywords

IL 10; IL 4; LPS; M1 and M2 polarization; Neuroinflammation

Indexed keywords

CXCL2 CHEMOKINE; G PROTEIN COUPLED RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID 1; LYSOPHOSPHATIDIC ACID 2; LYSOPHOSPHATIDIC ACID 4; LYSOPHOSPHATIDIC ACID 5; LYSOPHOSPHATIDIC ACID 6; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHATIDIC ACID RECEPTOR 3; LYSOPHOSPHATIDIC ACID RECEPTOR 5; LYSOPHOSPHATIDIC ACID RECEPTOR 6; RANTES; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ACTIN; BRP-LPA; CYTOKINE; LYSOPHOSPHOLIPID; MESSENGER RNA; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LYMPHOCYTE PROLIFERATION; MICROGLIA; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; BRAIN CORTEX; CELL CULTURE; CELL POLARITY; CLASSIFICATION; CYTOLOGY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; METABOLISM; NEWBORN; TIME FACTOR;

ACTINS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; CELL POLARITY; CELLS, CULTURED; CEREBRAL CORTEX; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; LYSOPHOSPHOLIPIDS; MICE; MICROGLIA; NITRIC OXIDE SYNTHASE TYPE II; REACTIVE OXYGEN SPECIES; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, MESSENGER; TIME FACTORS;

EID: 84983616254     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-016-0701-9     Document Type: Article

References (70)

1. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia. 2002;40(2):133-9.
2. Kettenmann H, Kirchhoff F, Verkhratsky A. Microglia: new roles for the synaptic stripper. Neuron. 2013;77(1):10-8. doi: 10.1016/j.neuron.2012.12.023.
3. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308(5726):1314-8. doi: 10.1126/science.1110647.
4. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 2009;64(1):110-22. doi: 10.1016/j.neuron.2009.08.039.
5. Aldskogius H. Regulation of microglia-potential new drug targets in the CNS. Expert Opin Ther Targets. 2001;5(6):655-68.
6. Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11(1):98. doi: 10.1186/1742-2094-11-98.
7. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 2008;1781(9):513-8. doi: 10.1016/j.bbalip.2008.06.005.
8. Ma L, Uchida H, Nagai J, Inoue M, Aoki J, Ueda H. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain. J Pharmacol Exp Ther. 2010;333(2):540-6. doi: 10.1124/jpet.109.164830.
9. Shindou H, Hishikawa D, Harayama T, Yuki K, Shimizu T. Recent progress on acyl CoA: lysophospholipid acyltransferase research. J Lipid Res. 2009;50(Suppl):S46-51. doi: 10.1194/jlr.R800035-JLR200.
10. Moolenaar WH, Perrakis A. Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol. 2011;12(10):674-9. doi: 10.1038/nrm3188.
11. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002;158(2):227-33. doi: 10.1083/jcb.200204026.
12. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006;281(35):25822-30. doi: 10.1074/jbc.M605142200.
13. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol. 2006;26(13):5015-22. doi: 10.1128/MCB.02419-05.
14. Fotopoulou S, Oikonomou N, Grigorieva E, Nikitopoulou I, Paparountas T, Thanassopoulou A, et al. ATX expression and LPA signalling are vital for the development of the nervous system. Dev Biol. 2010;339(2):451-64. doi: 10.1016/j.ydbio.2010.01.007.
15. Giganti A, Rodriguez M, Fould B, Moulharat N, Coge F, Chomarat P, et al. Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization. J Biol Chem. 2008;283(12):7776-89. doi: 10.1074/jbc.M708705200.
16. Triebl A, Trotzmuller M, Eberl A, Hanel P, Hartler J, Kofeler HC. Quantitation of phosphatidic acid and lysophosphatidic acid molecular species using hydrophilic interaction liquid chromatography coupled to electrospray ionization high resolution mass spectrometry. J Chromatogr A. 2014;1347:104-10. doi: 10.1016/j.chroma.2014.04.070.
17. Tigyi G, Hong L, Yakubu M, Parfenova H, Shibata M, Leffler CW. Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am J Phys. 1995;268(5 Pt 2):H2048-55.
18. Sun GY, Lu FL, Lin SE, Ko MR. Decapitation ischemia-induced release of free fatty acids in mouse brain. Relationship with diacylglycerols and lysophospholipids. Mol Chem Neuropathol. 1992;17(1):39-50.
19. Santos-Nogueira E, Lopez-Serrano C, Hernandez J, Lago N, Astudillo AM, Balsinde J, et al. Activation of lysophosphatidic acid receptor type 1 contributes to pathophysiology of spinal cord injury. J Neurosci. 2015;35(28):10224-35. doi: 10.1523/JNEUROSCI.4703-14.2015.
20. Choi JW, Chun J. Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta. 2013;1831(1):20-32. doi: 10.1016/j.bbalip.2012.07.015.
21. Yung YC, Stoddard NC, Mirendil H, Chun J. Lysophosphatidic acid signaling in the nervous system. Neuron. 2015;85(4):669-82. doi: 10.1016/j.neuron.2015.01.009.
22. Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol. 2014;171(15):3575-94. doi: 10.1111/bph.12678.
23. On NH, Savant S, Toews M, Miller DW. Rapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid. J Cereb Blood Flow Metab. 2013;33(12):1944-54. doi: 10.1038/jcbfm.2013.154.
24. Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol. 1996;135(4):1071-83.
25. Trimbuch T, Beed P, Vogt J, Schuchmann S, Maier N, Kintscher M, et al. Synaptic PRG-1 modulates excitatory transmission via lipid phosphate-mediated signaling. Cell. 2009;138(6):1222-35. doi: 10.1016/j.cell.2009.06.050.
26. Weiner JA, Hecht JH, Chun J. Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J Comp Neurol. 1998;398(4):587-98.
27. Bernhart E, Kollroser M, Rechberger G, Reicher H, Heinemann A, Schratl P, et al. Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture. Proteomics. 2010;10(1):141-58. doi: 10.1002/pmic.200900195.
28. Moller T, Contos JJ, Musante DB, Chun J, Ransom BR. Expression and function of lysophosphatidic acid receptors in cultured rodent microglial cells. J Biol Chem. 2001;276(28):25946-52. doi: 10.1074/jbc.M102691200.
29. Schilling T, Stock C, Schwab A, Eder C. Functional importance of Ca2+-activated K+ channels for lysophosphatidic acid-induced microglial migration. Eur J Neurosci. 2004;19(6):1469-74. doi: 10.1111/j.1460-9568.2004.03265.x.
30. Muessel MJ, Harry GJ, Armstrong DL, Storey NM. SDF-1alpha and LPA modulate microglia potassium channels through rho gtpases to regulate cell morphology. Glia. 2013;61(10):1620-8. doi: 10.1002/glia.22543.
31. Fujita R, Ma Y, Ueda H. Lysophosphatidic acid-induced membrane ruffling and brain-derived neurotrophic factor gene expression are mediated by ATP release in primary microglia. J Neurochem. 2008;107(1):152-60. doi: 10.1111/j.1471-4159.2008.05599.x.
32. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol. 2012;30:69-94. doi: 10.1146/annurev-immunol-020711-075011.
33. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol. 2008;9(4):415-23. doi: 10.1038/ni1573.
34. Nakasaki T, Tanaka T, Okudaira S, Hirosawa M, Umemoto E, Otani K, et al. Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am J Pathol. 2008;173(5):1566-76. doi: 10.2353/ajpath.2008.071153.
35. Knowlden S, Georas SN. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. J Immunol. 2014;192(3):851-7. doi: 10.4049/jimmunol.1302831.
36. Bai Z, Cai L, Umemoto E, Takeda A, Tohya K, Komai Y, et al. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis. J Immunol. 2013;190(5):2036-48. doi: 10.4049/jimmunol.1202025.
37. Chen R, Roman J, Guo J, West E, McDyer J, Williams MA, et al. Lysophosphatidic acid modulates the activation of human monocyte-derived dendritic cells. Stem Cells Dev. 2006;15(6):797-804. doi: 10.1089/scd.2006.15.797.
38. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol. 2011;11(11):775-87. doi: 10.1038/nri3086.
39. Zhao X, Wang H, Sun G, Zhang J, Edwards NJ, Aronowski J. Neuronal Interleukin-4 as a modulator of microglial pathways and ischemic brain damage. J Neurosci. 2015;35(32):11281-91. doi: 10.1523/JNEUROSCI.1685-15.2015.
40. Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2015. doi: 10.1111/bph.13139.
41. Deierborg T. Preparation of primary microglia cultures from postnatal mouse and rat brains. Methods Mol Biol. 2013;1041:25-31. doi: 10.1007/978-1-62703-520-0_4.
42. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. doi: 10.1006/meth.2001.1262.
43. McCall MN, McMurray HR, Land H, Almudevar A. On non-detects in qPCR data. Bioinformatics. 2014;30(16):2310-6. doi: 10.1093/bioinformatics/btu239.
44. Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res. 2014. doi: 10.1194/jlr.R046458.
45. Kozian DH, Evers A, Florian P, Wonerow P, Joho S, Nazare M. Selective non-lipid modulator of LPA5 activity in human platelets. Bioorg Med Chem Lett. 2012;22(16):5239-43. doi: 10.1016/j.bmcl.2012.06.057.
46. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol. 2004;142(2):231-55. doi: 10.1038/sj.bjp.0705776.
47. Chhor V, Le Charpentier T, Lebon S, Ore MV, Celador IL, Josserand J, et al. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun. 2013;32:70-85. doi: 10.1016/j.bbi.2013.02.005.
48. Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16(12):1896-905. doi: 10.1038/nn.3554.
49. Savaskan NE, Rocha L, Kotter MR, Baer A, Lubec G, van Meeteren LA, et al. Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma. Cell Mol Life Sci. 2007;64(2):230-43. doi: 10.1007/s00018-006-6412-0.
50. Yung YC, Mutoh T, Lin ME, Noguchi K, Rivera RR, Choi JW, et al. Lysophosphatidic acid signaling may initiate fetal hydrocephalus. Sci Transl Med. 2011;3(99):99ra87. doi: 10.1126/scitranslmed.3002095.
51. Crack PJ, Zhang M, Morganti-Kossmann MC, Morris AJ, Wojciak JM, Fleming JK, et al. Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. J Neuroinflammation. 2014;11:37. doi: 10.1186/1742-2094-11-37.
52. Ma L, Uchida H, Nagai J, Inoue M, Chun J, Aoki J, et al. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain. Mol Pain. 2009;5:64. doi: 10.1186/1744-8069-5-64.
53. Ueda H, Matsunaga H, Olaposi OI, Nagai J. Lysophosphatidic acid: chemical signature of neuropathic pain. Biochim Biophys Acta. 2013;1831(1):61-73. doi: 10.1016/j.bbalip.2012.08.014.
54. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med. 2004;10(7):712-8. doi: 10.1038/nm1060.
55. Lin ME, Rivera RR, Chun J. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain. J Biol Chem. 2012;287(21):17608-17. doi: 10.1074/jbc.M111.330183.
56. Ma L, Nagai J, Ueda H. Microglial activation mediates de novo lysophosphatidic acid production in a model of neuropathic pain. J Neurochem. 2010;115(3):643-53. doi: 10.1111/j.1471-4159.2010.06955.x.
57. Zhao C, Fernandes MJ, Prestwich GD, Turgeon M, Di Battista J, Clair T, et al. Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis? Mol Pharmacol. 2008;73(2):587-600. doi: 10.1124/mol.107.038216.
58. Kumar A, Chen SH, Kadiiska MB, Hong JS, Zielonka J, Kalyanaraman B, et al. Inducible nitric oxide synthase is key to peroxynitrite-mediated, LPS-induced protein radical formation in murine microglial BV2 cells. Free Radic Biol Med. 2014;73:51-9. doi: 10.1016/j.freeradbiomed.2014.04.014.
59. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol. 2004;286(3):R431-44. doi: 10.1152/ajpregu.00361.2003.
60. Ebadi M, Sharma SK. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Signal. 2003;5(3):319-35. doi: 10.1089/152308603322110896.
61. Baud O, Li J, Zhang Y, Neve RL, Volpe JJ, Rosenberg PA. Nitric oxide-induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis-inducing factor translocation. Eur J Neurosci. 2004;20(7):1713-26. doi: 10.1111/j.1460-9568.2004.03616.x.
62. Ding R, Chen Y, Yang S, Deng X, Fu Z, Feng L, et al. Blood-brain barrier disruption induced by hemoglobin in vivo: Involvement of up-regulation of nitric oxide synthase and peroxynitrite formation. Brain Res. 2014;1571:25-38. doi: 10.1016/j.brainres.2014.04.042.
63. Awada R, Rondeau P, Gres S, Saulnier-Blache JS, Lefebvre d'Hellencourt C, Bourdon E. Autotaxin protects microglial cells against oxidative stress. Free Radic Biol Med. 2012;52(2):516-26. doi: 10.1016/j.freeradbiomed.2011.11.014.
64. Awada R, Saulnier-Blache JS, Gres S, Bourdon E, Rondeau P, Parimisetty A, et al. Autotaxin downregulates LPS-induced microglia activation and pro-inflammatory cytokines production. J Cell Biochem. 2014;115(12):2123-32. doi: 10.1002/jcb.24889.
65. Fan H, Zingarelli B, Harris V, Tempel GE, Halushka PV, Cook JA. Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-inflammatory response: potential anti-inflammatory signaling pathways. Mol Med. 2008;14(7-8):422-8. doi: 10.2119/2007-00106.Fan.
66. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev. 2011;91(2):461-553. doi: 10.1152/physrev.00011.2010.
67. Aly H, Khashaba MT, El-Ayouty M, El-Sayed O, Hasanein BM. IL-1beta, IL-6 and TNF-alpha and outcomes of neonatal hypoxic ischemic encephalopathy. Brain Dev. 2006;28(3):178-82. doi: 10.1016/j.braindev.2005.06.006.
68. Gyoneva S, Ransohoff RM. Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines. Trends Pharmacol Sci. 2015;36(7):471-80. doi: 10.1016/j.tips.2015.04.003.
69. Kozian DH, von Haeften E, Joho S, Czechtizky W, Anumala UR, Roux P, et al. Modulation of hexadecyl-LPA-mediated activation of mast cells and microglia by a chemical probe for LPA5. Chembiochem. 2016;17(9):861-5. doi: 10.1002/cbic.201500559.
70. Lundequist A, Boyce JA. LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1beta release. PLoS One. 2011;6(3):e18192. doi: 10.1371/journal.pone.0018192.